

Electronic Acknowledgement Receipt

EFS ID:	4474678
Application Number:	10644579
International Application Number:	
Confirmation Number:	5200
Title of Invention:	Use of enantiomeric pure escitalopram
First Named Inventor/Applicant Name:	Connie Sanchez
Customer Number:	07278
Filer:	Marie Louise Collazo/Judi Cordo
Filer Authorized By:	Marie Louise Collazo
Attorney Docket Number:	05432/100M919-US1
Receipt Date:	17-DEC-2008
Filing Date:	20-AUG-2003
Time Stamp:	15:42:33
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS_for_filing.PDF	636600 acbbabf7250084be235a0b07246003868a1c5bd4	yes	8

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement Letter		1	4	
	Information Disclosure Statement (IDS) Filed (SB/08)		5	8	
Warnings:					
Information:					
2	NPL Documents	NPL_Takeshi_Article.PDF	581100	no	7
			c45c5085094f7a73b7bbcd9703b2f44a529f35d		
Warnings:					
Information:					
3	NPL Documents	NPL_Hexal_Opposition.PDF	665055	no	17
			425a9cdd67a3f1174946fca648d69255da5fcd67		
Warnings:					
Information:					
4	NPL Documents	NPL_Lepola_Effect_of_Citalopram_Article.PDF	366953	no	5
			1417ce7f66ec6d2671d2c84cba7c4e943436fb29		
Warnings:					
Information:					
5	NPL Documents	NPL_Lepola_Citalopram_in_Anxiety_Article.PDF	236636	no	3
			bb8c15c81211a7daffa7a2db43ef2156ccce5d1		
Warnings:					
Information:					
6	NPL Documents	NPL_Ragneskog_Article.PDF	663169	no	10
			60e6a557bad24cabca7d873809eb852c8d866219		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
7	Foreign Reference	EP_0814084.PDF	1380060	no	26
			8dcb795a20c385684b4d537bef057915d2672a86		
Warnings:					
Information:					
8	Foreign Reference	WO_0112175.PDF	1599541	no	43
			c373379056d409bebd2062dc1c588ff5ad7d1f0f		
Warnings:					

Information:					
9	NPL Documents	NPL_Hogg_Article.PDF	119290	no	2
			141982c3dac3941e337212412285d89097962b96		
Warnings:					
Information:					
10	NPL Documents	NPL_Generics_Opposition.PDF	617942	no	17
			25604e9b24fabcff9e5fb067b530909a22f809d1		
Warnings:					
Information:					
11	NPL Documents	NPL_Gedeon_Opposition.PDF	505187	no	15
			e6a8177a7973f2008d65abd0fd15043062eb58ef		
Warnings:					
Information:					
12	NPL Documents	NPL_Pilva_Opposition.PDF	653468	no	20
			3e28e2944dabaff05424f81c67eff04b350e3c06		
Warnings:					
Information:					
13	NPL Documents	NPL_Teva_Opposition.PDF	736251	no	19
			5ed962fa6675bba0e182760bdc434b1bd736a116		
Warnings:					
Information:					
14	NPL Documents	NPL_Forest_Article.PDF	166551	no	3
			a0c22e14de53e91f9cf74bb870a1145356a1a3cc		
Warnings:					
Information:					
15	NPL Documents	NPL_Noble_Article.PDF	1594373	no	22
			59ad974b0f3fce7f5204429146682c8691adeec4		
Warnings:					
Information:					
16	NPL Documents	NPL_Baumann_Article.PDF	697157	no	9
			251339ce8fed5dce9938de784c469fcb57205d1		
Warnings:					
Information:					
17	Foreign Reference	WO_9913877.PDF	2820490	no	75
			4cc173032e0885c38b0c441c885dc37ba581e73b		
Warnings:					

Information:					
18	NPL Documents	NPL_Emmanuel_Article.PDF	59540	no	1
			819c65cb152ba9ef7a1bdd0e15f4c3bf087d1de6		
Warnings:					
Information:					
19	NPL Documents	NPL_Parker_Article.PDF	647574	no	8
			f384e0a3f7ab02a1849983aca9012989f3e797f7		
Warnings:					
Information:					
20	NPL Documents	NPL_Laux_Article.pdf	70714	no	5
			f79ea0a0affd448b0e21e1746a61e292e6ca1ea9		
Warnings:					
Information:					
21	NPL Documents	NPL_Egis_Opposition.pdf	1319773	no	31
			3d00d73fda3744e0a563887ab4dea48666a58be5		
Warnings:					
Information:					
22	NPL Documents	NPL_Connor_Article.PDF	757270	no	9
			ddf136ad8c17f8bc7dc8b804ffd09ddbe0f592bb		
Warnings:					
Information:					
23	NPL Documents	NPL_Uhlenhuth_Article.PDF	780877	no	10
			5b62362c89645360a71f4fbb51825edb2fd1e02		
Warnings:					
Information:					
24	NPL Documents	NPL_Fachinformation_Ciprallex_10mg_20mg.PDF	1175139	no	10
			7a275aed34300190dbda3b202a8a0f1c617217fc		
Warnings:					
Information:					
25	NPL Documents	NPL_FDA's_Policy_Statement.PDF	396488	no	6
			b382b0b0f60ffd968797731e287723c74736bb77		
Warnings:					
Information:					
26	NPL Documents	NPL_Cipramil_20_mg_40_mg.PDF	596574	no	5
			a2032928dd74fff1b78c0285c8bbd553cf7b1d5		
Warnings:					

Information:					
27	NPL Documents	NPL_Lydiard_Article.PDF	958330	no	9
			b83198fc3a574729fc4e8202899cf3f8d5d26b4d		
Warnings:					
Information:					
28	NPL Documents	NPL_Brawman_Article.PDF	333567	no	3
			66ce2369479c96cf769e7a509d0a662b87c8d473		
Warnings:					
Information:					
29	NPL Documents	NPL_Rocca_Article.PDF	558452	no	7
			18faf9f532e59a45e0b1f941650721874727e152		
Warnings:					
Information:					
30	NPL Documents	NPL_Silverstone_Article.PDF	870289	no	8
			4d9fb9f6297fc1dad2d448f11fe8d2456192b6a8		
Warnings:					
Information:					
31	NPL Documents	NPL_Hashimoto_Effects_of_the_Coadministration_Article.PDF	373283	no	5
			ece18c8dfccfe847dc2e6e1daf58fc5e14b74e71		
Warnings:					
Information:					
32	NPL Documents	NPL_Lundbeck_Annual_Report_1999.PDF	404079	no	3
			9b65b0df9f97f086ab9314a994df02a884d478af		
Warnings:					
Information:					
33	NPL Documents	NPL_Cutler_Article.PDF	786091	no	9
			3037a526a03c487aa12d919a580cdd71c51c4929		
Warnings:					
Information:					
34	NPL Documents	NPL_Culpepper_Article.PDF	516011	no	6
			eddff187ea55eff02dbfaabfe67afc60cf40aa6a4		
Warnings:					
Information:					
35	NPL Documents	NPL_Lundbeck_Annual_Report_1998.PDF	550650	no	3
			4c6f6f81cf7eb9c492418108506482de71d5c1a0		
Warnings:					

Information:					
36	NPL Documents	NPL_Rote_Liste.PDF	220710	no	3
			0a7f66e3d01ec2192e6935f42537b44705fa5841		
Warnings:					
Information:					
37	NPL Documents	NPL_Maier_Article.PDF	55747	no	2
			2119e92f88e1eb63f226c5c38fc968588b6777c6		
Warnings:					
Information:					
38	NPL Documents	NPL_Bondolfi_Article.PDF	612215	no	5
			79eaa67d98b98e691bff1e72cc9651f6e996926		
Warnings:					
Information:					
39	NPL Documents	NPL_Hashimoto_Effects_of_Conditioned_Article.PDF	698556	no	8
			230207606eabdad9fb027d447b70a0515fc14372		
Warnings:					
Information:					
40	NPL Documents	NPL_Sidhu_Article.PDF	536814	no	7
			a4d8168e37dd4b30e2357fcb9f42cc8c64e9a85c		
Warnings:					
Information:					
41	NPL Documents	NPL_Hutt_Article.PDF	772646	no	12
			649066873f441d0c02a8a5f42329778670428a11		
Warnings:					
Information:					
42	NPL Documents	NPL_Kosel_Article.PDF	244003	no	5
			0831aa2ed329d355a5a23f5b5926ca98fc9afaceb		
Warnings:					
Information:					
43	NPL Documents	NPL_Hashimoto_Serotonin_Article.PDF	461345	no	5
			854d1e5249d3de46ada413f41cdd6012e505b57e		
Warnings:					
Information:					
44	NPL Documents	NPL_Richels_Article.PDF	1185723	no	12
			1038b20d290b3392a4664dbc061bf75ac51c32c		
Warnings:					

Information:					
45	NPL Documents	NPL_Lhuillier_Article.PDF	182134	no	4
			8345e5050fdea260b746e8f8c0111a8df42bc8a2		
Warnings:					
Information:					
46	NPL Documents	NPL_Boerner_Article.PDF	923775	no	8
			027f05b23438db6bedb79f98ab9d3bca5e6faa88		
Warnings:					
Information:					
47	NPL Documents	NPL_Rochat_Article.PDF	572981	no	8
			7ab18dc9c279d98e0b260fba9227e19b34bf7fce		
Warnings:					
Information:					
48	NPL Documents	NPL_NZ_Examination_Report.PDF	83998	no	3
			44b8ae01161675e43989fe554e55c6d8702ded0d		
Warnings:					
Information:					
49	NPL Documents	NPL_Sorbera_Article.PDF	510054	no	6
			aed5878c9c706047b23b7d8f33dbaff2e713d27		
Warnings:					
Information:					
Total Files Size (in bytes):			32255225		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					